



# Summary of Investigation Results

## Preparations containing clopidogrel sulfate

January 17, 2023

### Non-proprietary name

- a. Clopidogrel sulfate
- b. Clopidogrel sulfate/aspirin

### Brand name (marketing authorization holder)

- a. Plavix Tablets 25 mg, 75 mg (Sanofi K.K.), and the others
- b. ComPlavin Combination Tablets (Sanofi K.K.), and the others

### Japanese market launch

- a. May 2006
- b. December 2013

### Indications

- a. Clopidogrel sulfate
  - Prevention of recurrence following ischaemic cerebrovascular disorder (except cardioembolic stroke)
  - The following ischaemic heart diseases for which percutaneous coronary intervention (PCI) is indicated:
    - Acute coronary syndromes (unstable angina, non-ST-elevation myocardial infarction, ST-elevation myocardial infarction)
    - Stable angina pectoris, old myocardial infarction
  - Prevention of thrombus/embolus formation in peripheral arterial disease
- b. Clopidogrel sulfate/aspirin
  - The following ischaemic heart diseases for which percutaneous coronary intervention (PCI) is indicated:



- Acute coronary syndromes (unstable angina, non-ST-elevation myocardial infarction, ST-elevation myocardial infarction)
- Stable angina pectoris, old myocardial infarction

### Summary of revisions

1. “Insulin autoimmune syndrome” should be added to the Clinically Significant Adverse Reactions section.
2. In connection with 1. above, the existing language concerning insulin autoimmune syndrome in the Other Precautions section should be revised.

### Investigation results and background of the revision

Cases involving insulin autoimmune syndrome reported in Japan were evaluated. Cases for which a causal relationship between preparations containing clopidogrel sulfate and insulin autoimmune syndrome have been reported in Japan. As a result of consultation with expert advisors regarding the causality assessment of the cases and the necessity of revision of Precautions, MHLW/PMDA concluded that revision of Precautions was necessary.

### Reference: Number of cases\* and patient mortalities involving insulin autoimmune syndrome reported in Japan

#### a. Clopidogrel sulfate

A total of 12 cases have been reported to date (including 8 cases for which a causal relationship between the drug and event was reasonably possible).

No patient mortalities have been reported to date.

#### b. Clopidogrel sulfate/aspirin

No cases have been reported to date.

\*Cases collected in the PMDA's database for adverse drug reactions, etc. reports

The expert advisors present at the Expert Discussion regarding the current investigation were nominated based on their conflict of interest declarations concerning the relevant products, pursuant to the “Rules for Convening Expert Discussions, etc., by the Pharmaceuticals and Medical Devices Agency” (PMDA Administrative Rule No. 20-8, dated December 25, 2008).